

18<sup>th</sup> October, 2023

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex, Bandra  
(East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Intimation of Conference Call with Investors/Analysts under the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015 ('Listing Regulations')**

Dear Sir / Madam,

Pursuant to Regulation 30(6) of the Listing Regulations, please find enclosed herewith the details of the Conference Call with investors/ analysts.

Kindly take this on record.

Thanking you,

Yours truly,

For **Piramal Pharma Limited**

**Tanya Sanish**  
Company Secretary

## Q2 and H1 FY2024 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on **30<sup>th</sup> October 2023** at **9:00 AM to 9:45 AM (IST)** to discuss its **Q2 and H1 FY2024 Results**.

The dial-in details for the call are as under:

Event	Location & Time	Telephone Number
Conference call on 30 <sup>th</sup> October, 2023	India – 09:00 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 11:30 PM (Eastern Time – New York)	Toll free number 18667462133
	UK – 3:30 AM (London Time)	Toll free number 08081011573
	Singapore – 11:30 AM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 11:30 AM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – <a href="https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7279153&amp;linkSecurityString=28e77c0997">https://services.choruscall.in/DiamondPassRegistration/register?confirmationNumber=7279153&amp;linkSecurityString=28e77c0997</a>	

### About Piramal Pharma Ltd:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17 global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and the India Consumer Healthcare business, selling over-the-counter products. In addition, one of PPL's associate companies, Allergan India Private Limited is a JV with AbbVie Inc. and has emerged as one of the market leaders in the ophthalmology therapy area. Further, PPL has a minority investment in Yapan Bio Private Limited. In October 2020, PPL received a 20% strategic growth investment from the Carlyle Group.

For more information visit: [www.piramal.com/pharma](http://www.piramal.com/pharma) | [LinkedIn](#) | [Facebook](#) | [Twitter](#)

#### For Media Queries:

Rajiv Banerjee  
Group Head - Corporate Communications  
[rajiv.banerjee@piramal.com](mailto:rajiv.banerjee@piramal.com)

#### For Investors:

Gagan Borana  
General Manager - Investor Relations & Sustainability  
[gagan.borana@piramal.com](mailto:gagan.borana@piramal.com)

#### Piramal Pharma Limited

CIN: U24297MH2020PLC338592

Registered Office: Gr. Flr. Piramal Ananta, Agastya Corporate Park, Opp Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai – 400070 India T +91 22 3802 3000 / 4000

[piramal.com](http://piramal.com)